JNJ
Johnson & Johnson
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for Johnson & Johnson.
Johnson & Johnson researches, develops, manufactures, and sells pharmaceutical and medical-device products worldwide. Innovative Medicine includes immunology, oncology, neuroscience, pulmonary hypertension, and infectious-disease therapies. MedTech includes surgery, orthopaedics, interventional solutions, and vision products. The company divested its consumer-health business as Kenvue.
Coverage
Medicaid's MFN Rebate Stacks on a 62-77% Discount. Mississippi Already Beats It.
The White House will say all 50 states get most-favored-nation Medicaid pricing. It stacks on existing rebates, and a July study says Mississippi wins now.
J&J Won the First-Ever wAIHA Approval on Nine Responders in 38. The Effect's Lower Bound Is 0.1 Points.
J&J's Imaavy is the first drug ever approved for wAIHA: nine of 38 responded against three of 39 on placebo, a 16-point gap whose 95% interval starts at 0.1.
Johnson & Johnson's First $25 Billion Quarter Produced $3 Million Less Net Income Than the Year Before.
J&J's first $25B quarter — its largest ever — produced $3M less GAAP net income than a year earlier. The gap is amortization, litigation and separation costs.
Johnson & Johnson Guided to $100 Billion. It Has Never Reported a $25 Billion Quarter, and It Now Needs Three.
J&J reports July 15 needing an average of $25.58B across three quarters to hit guidance — above the largest quarter it has ever reported, the $24.56B record.
Where the revenue goes next
Latest: $25.31B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $21.08B |
| 2020Q4 | $22.48B |
| 2021Q1 | $22.32B |
| 2021Q2 | $23.31B |
| 2021Q3 | $23.34B |
| 2021Q4 | $9.77B |
| 2022Q1 | $23.43B |
| 2022Q2 | $24.02B |
| 2022Q3 | $20.00B |
| 2022Q4 | $12.55B |
| 2023Q1 | $20.89B |
| 2023Q2 | $21.52B |
| 2023Q3 | $21.35B |
| 2023Q4 | $21.39B |
| 2024Q1 | $21.38B |
| 2024Q2 | $22.45B |
| 2024Q3 | $22.47B |
| 2024Q4 | $22.52B |
| 2025Q1 | $21.89B |
| 2025Q2 | $23.74B |
| 2025Q3 | $23.99B |
| 2025Q4 | $24.56B |
| 2026Q1 | $24.06B |
| 2026Q2 | $25.31B |
Latest: $2.27 (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $1.33 |
| 2020Q4 | $0.65 |
| 2021Q1 | $2.32 |
| 2021Q2 | $2.35 |
| 2021Q3 | $1.37 |
| 2021Q4 | $1.77 |
| 2022Q1 | $1.93 |
| 2022Q2 | $1.80 |
| 2022Q3 | $1.68 |
| 2022Q4 | $1.32 |
| 2023Q1 | −$0.03 |
| 2023Q2 | $1.96 |
| 2023Q3 | $10.21 |
| 2023Q4 | $1.58 |
| 2024Q1 | $1.34 |
| 2024Q2 | $1.93 |
| 2024Q3 | $1.11 |
| 2024Q4 | $1.41 |
| 2025Q1 | $4.54 |
| 2025Q2 | $2.29 |
| 2025Q3 | $2.12 |
| 2025Q4 | $2.10 |
| 2026Q1 | $2.14 |
| 2026Q2 | $2.27 |
Latest: 29.4 (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | 20.2 |
| 2020Q4 | 24.8 |
| 2021Q1 | 25.4 |
| 2021Q2 | 21.8 |
| 2021Q3 | 21.3 |
| 2021Q4 | 19.5 |
| 2022Q1 | 21.4 |
| 2022Q2 | 23.3 |
| 2022Q3 | 20.6 |
| 2022Q4 | 23.9 |
| 2023Q1 | 29.8 |
| 2023Q2 | 31.0 |
| 2023Q3 | 10.8 |
| 2023Q4 | 10.7 |
| 2024Q1 | 9.3 |
| 2024Q2 | 8.7 |
| 2024Q3 | 22.6 |
| 2024Q4 | 21.1 |
| 2025Q1 | 18.0 |
| 2025Q2 | 16.1 |
| 2025Q3 | 17.8 |
| 2025Q4 | 18.7 |
| 2026Q1 | 28.3 |
| 2026Q2 | 29.4 |
Latest: $7.29B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $7.66B |
| 2020Q4 | $7.22B |
| 2021Q1 | $4.00B |
| 2021Q2 | $4.55B |
| 2021Q3 | $7.55B |
| 2021Q4 | $4.36B |
| 2022Q1 | $3.62B |
| 2022Q2 | $4.78B |
| 2022Q3 | $5.34B |
| 2022Q4 | $3.98B |
| 2023Q1 | $2.43B |
| 2023Q2 | $3.13B |
| 2023Q3 | $6.64B |
| 2023Q4 | $6.39B |
| 2024Q1 | $3.06B |
| 2024Q2 | $5.02B |
| 2024Q3 | $7.01B |
| 2024Q4 | $5.42B |
| 2025Q1 | $3.66B |
| 2025Q2 | $2.89B |
| 2025Q3 | $8.09B |
| 2025Q4 | $5.47B |
| 2026Q1 | $1.47B |
| 2026Q2 | $7.29B |
Latest: 2.41B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | 2.67B |
| 2020Q4 | 2.63B |
| 2021Q1 | 2.67B |
| 2021Q2 | 2.67B |
| 2021Q3 | 2.67B |
| 2021Q4 | 2.63B |
| 2022Q1 | 2.67B |
| 2022Q2 | 2.67B |
| 2022Q3 | 2.66B |
| 2022Q4 | 2.61B |
| 2023Q1 | 2.61B |
| 2023Q2 | 2.63B |
| 2023Q3 | 2.55B |
| 2023Q4 | 2.41B |
| 2024Q1 | 2.43B |
| 2024Q2 | 2.42B |
| 2024Q3 | 2.43B |
| 2024Q4 | 2.41B |
| 2025Q1 | 2.42B |
| 2025Q2 | 2.42B |
| 2025Q3 | 2.43B |
| 2025Q4 | 2.41B |
| 2026Q1 | 2.45B |
| 2026Q2 | 2.41B |
Latest: $288.21B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $174.79B |
| 2020Q4 | $182.02B |
| 2021Q1 | $186.02B |
| 2021Q2 | $190.57B |
| 2021Q3 | $198.13B |
| 2021Q4 | $202.49B |
| 2022Q1 | $206.11B |
| 2022Q2 | $210.89B |
| 2022Q3 | $216.23B |
| 2022Q4 | $220.22B |
| 2023Q1 | $222.65B |
| 2023Q2 | $225.78B |
| 2023Q3 | $232.43B |
| 2023Q4 | $238.82B |
| 2024Q1 | $241.88B |
| 2024Q2 | $246.90B |
| 2024Q3 | $253.92B |
| 2024Q4 | $259.34B |
| 2025Q1 | $263.00B |
| 2025Q2 | $265.89B |
| 2025Q3 | $273.97B |
| 2025Q4 | $279.45B |
| 2026Q1 | $280.91B |
| 2026Q2 | $288.21B |
Latest earnings
Next report: Oct 13, 2026 (Q3 2026)
Company History
Three brothers founded the company in New Brunswick, New Jersey, producing ready-to-use sterile surgical dressings with 14 employees.
Designed to support railroad workers far from medical care, including antiseptic supplies and field use directions.
Earle Dickson combined adhesive tape and gauze to create the first commercial adhesive bandage, sold starting 1921.
Robert Wood Johnson wrote
Cyanide-laced Tylenol led to a nationwide recall of 31 million bottles; company response set industry standards for crisis management.
$30 billion deal, the largest in company history, expanding pharmaceutical capabilities.
$16.6 billion purchase of cardiovascular medical technology company to bolster MedTech segment.
Consumer health division went public as Kenvue in May 2023, with J&J retaining minimal stake by 2024.
Acquired Intra-Cellular Therapies for $14.6B in January 2025, continuing aggressive M&A strategy.
Key Players
showing 6 of 21
The CEO view — 5 podcasts, interviews & articles →
Similar stocks in Healthcare
Funds we follow holding JNJ
By latest reported 13F position value. Market value at quarter-end, not cost basis.
